Cargando…

Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus

BACKGROUND: The amyloid-β oligomers, consisting of 10–20 monomers (AβO(10–20)), have strong neurotoxicity and are associated with cognitive impairment in Alzheimer’s disease (AD). However, their role in patients with idiopathic normal pressure hydrocephalus (iNPH) is poorly understood. OBJECTIVE: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawamura, Kaito, Miyajima, Masakazu, Nakajima, Madoka, Kanai, Mitsuyasu, Motoi, Yumiko, Nojiri, Shuko, Akiba, Chihiro, Ogino, Ikuko, Xu, Hanbing, Kamohara, Chihiro, Yamada, Shinya, Karagiozov, Kostadin, Ikeuchi, Takeshi, Kondo, Akihide, Arai, Hajime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461658/
https://www.ncbi.nlm.nih.gov/pubmed/34275898
http://dx.doi.org/10.3233/JAD-210226
_version_ 1784572034446000128
author Kawamura, Kaito
Miyajima, Masakazu
Nakajima, Madoka
Kanai, Mitsuyasu
Motoi, Yumiko
Nojiri, Shuko
Akiba, Chihiro
Ogino, Ikuko
Xu, Hanbing
Kamohara, Chihiro
Yamada, Shinya
Karagiozov, Kostadin
Ikeuchi, Takeshi
Kondo, Akihide
Arai, Hajime
author_facet Kawamura, Kaito
Miyajima, Masakazu
Nakajima, Madoka
Kanai, Mitsuyasu
Motoi, Yumiko
Nojiri, Shuko
Akiba, Chihiro
Ogino, Ikuko
Xu, Hanbing
Kamohara, Chihiro
Yamada, Shinya
Karagiozov, Kostadin
Ikeuchi, Takeshi
Kondo, Akihide
Arai, Hajime
author_sort Kawamura, Kaito
collection PubMed
description BACKGROUND: The amyloid-β oligomers, consisting of 10–20 monomers (AβO(10–20)), have strong neurotoxicity and are associated with cognitive impairment in Alzheimer’s disease (AD). However, their role in patients with idiopathic normal pressure hydrocephalus (iNPH) is poorly understood. OBJECTIVE: We hypothesized that cerebrospinal fluid (CSF) AβO(10–20) accumulates in patients with iNPH, and its clearance after CSF shunting contributes to neurological improvement. We measured CSF AβO(10–20) levels before and after CSF shunting in iNPH patients evaluating their diagnostic and prognostic role. METHODS: We evaluated two iNPH cohorts: “evaluation” (cohort-1) with 32 patients and “validation” (cohort-2) with 13 patients. Comparison cohorts included: 27 neurologically healthy controls (HCs), and 16 AD, 15 Parkinson’s disease (PD), and 14 progressive supranuclear palsy (PSP) patients. We assessed for all cohorts CSF AβO(10–20) levels and their comprehensive clinical data. iNPH cohort-1 pre-shunting data were compared with those of comparison cohorts, using cohort-2 for validation. Next, we compared cohort-1’s clinical and CSF data: 1) before and after CSF shunting, and 2) increased versus decreased AβO(10–20) levels at baseline, 1 and 3 years after shunting. RESULTS: Cohort-1 had higher CSF AβO(10–20) levels than the HCs, PD, and PSP cohorts. This result was validated with data from cohort-2. CSF AβO(10–20) levels differentiated cohort-1 from the PD and PSP groups, with an area under receiver operating characteristic curve of 0.94. AβO(10–20) levels in cohort-1 decreased after CSF shunting. Patients with AβO(10–20) decrease showed better cognitive outcome than those without. CONCLUSION: AβO(10–20) accumulates in patients with iNPH and is eliminated by CSF shunting. AβO(10–20) can be an applicable diagnostic and prognostic biomarker.
format Online
Article
Text
id pubmed-8461658
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-84616582021-10-08 Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus Kawamura, Kaito Miyajima, Masakazu Nakajima, Madoka Kanai, Mitsuyasu Motoi, Yumiko Nojiri, Shuko Akiba, Chihiro Ogino, Ikuko Xu, Hanbing Kamohara, Chihiro Yamada, Shinya Karagiozov, Kostadin Ikeuchi, Takeshi Kondo, Akihide Arai, Hajime J Alzheimers Dis Research Article BACKGROUND: The amyloid-β oligomers, consisting of 10–20 monomers (AβO(10–20)), have strong neurotoxicity and are associated with cognitive impairment in Alzheimer’s disease (AD). However, their role in patients with idiopathic normal pressure hydrocephalus (iNPH) is poorly understood. OBJECTIVE: We hypothesized that cerebrospinal fluid (CSF) AβO(10–20) accumulates in patients with iNPH, and its clearance after CSF shunting contributes to neurological improvement. We measured CSF AβO(10–20) levels before and after CSF shunting in iNPH patients evaluating their diagnostic and prognostic role. METHODS: We evaluated two iNPH cohorts: “evaluation” (cohort-1) with 32 patients and “validation” (cohort-2) with 13 patients. Comparison cohorts included: 27 neurologically healthy controls (HCs), and 16 AD, 15 Parkinson’s disease (PD), and 14 progressive supranuclear palsy (PSP) patients. We assessed for all cohorts CSF AβO(10–20) levels and their comprehensive clinical data. iNPH cohort-1 pre-shunting data were compared with those of comparison cohorts, using cohort-2 for validation. Next, we compared cohort-1’s clinical and CSF data: 1) before and after CSF shunting, and 2) increased versus decreased AβO(10–20) levels at baseline, 1 and 3 years after shunting. RESULTS: Cohort-1 had higher CSF AβO(10–20) levels than the HCs, PD, and PSP cohorts. This result was validated with data from cohort-2. CSF AβO(10–20) levels differentiated cohort-1 from the PD and PSP groups, with an area under receiver operating characteristic curve of 0.94. AβO(10–20) levels in cohort-1 decreased after CSF shunting. Patients with AβO(10–20) decrease showed better cognitive outcome than those without. CONCLUSION: AβO(10–20) accumulates in patients with iNPH and is eliminated by CSF shunting. AβO(10–20) can be an applicable diagnostic and prognostic biomarker. IOS Press 2021-08-31 /pmc/articles/PMC8461658/ /pubmed/34275898 http://dx.doi.org/10.3233/JAD-210226 Text en © 2021 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kawamura, Kaito
Miyajima, Masakazu
Nakajima, Madoka
Kanai, Mitsuyasu
Motoi, Yumiko
Nojiri, Shuko
Akiba, Chihiro
Ogino, Ikuko
Xu, Hanbing
Kamohara, Chihiro
Yamada, Shinya
Karagiozov, Kostadin
Ikeuchi, Takeshi
Kondo, Akihide
Arai, Hajime
Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus
title Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus
title_full Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus
title_fullStr Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus
title_full_unstemmed Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus
title_short Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus
title_sort cerebrospinal fluid amyloid-β oligomer levels in patients with idiopathic normal pressure hydrocephalus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461658/
https://www.ncbi.nlm.nih.gov/pubmed/34275898
http://dx.doi.org/10.3233/JAD-210226
work_keys_str_mv AT kawamurakaito cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT miyajimamasakazu cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT nakajimamadoka cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT kanaimitsuyasu cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT motoiyumiko cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT nojirishuko cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT akibachihiro cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT oginoikuko cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT xuhanbing cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT kamoharachihiro cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT yamadashinya cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT karagiozovkostadin cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT ikeuchitakeshi cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT kondoakihide cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus
AT araihajime cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus